Characterization of gut dominant microbiota in obese patients with nonalcoholic fatty liver disease
暂无分享,去创建一个
[1] J. Roblero,et al. The immune response as a therapeutic target in non-alcoholic fatty liver disease , 2022, Frontiers in Immunology.
[2] P. Wiklund,et al. A randomized controlled trial for response of microbiome network to exercise and diet intervention in patients with nonalcoholic fatty liver disease , 2022, Nature Communications.
[3] Dongya Zhang,et al. Microbiota in health and diseases , 2022, Signal Transduction and Targeted Therapy.
[4] V. Ayala,et al. NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective. , 2022, Gastroenterology.
[5] E. Comelli,et al. Relationship Between Hepatic Gene Expression, Intestinal Microbiota, and Inferred Functional Metagenomic Analysis in NAFLD , 2022, Clinical and translational gastroenterology.
[6] F. Bäckhed,et al. The Metabolic Role and Therapeutic Potential of the Microbiome , 2022, Endocrine reviews.
[7] F. Magkos,et al. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives , 2021, Biomolecules.
[8] V. Tremaroli,et al. Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism. , 2021, European heart journal.
[9] A. Rosengren. Obesity and cardiovascular health: the size of the problem , 2021, European heart journal.
[10] M. Honda,et al. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics , 2021, International journal of molecular sciences.
[11] Changtao Jiang,et al. Intestinal hypoxia-inducible factor 2α regulates lactate levels to shape the gut microbiome and alter thermogenesis. , 2021, Cell metabolism.
[12] Xusheng Guo,et al. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates , 2021, International journal of biological sciences.
[13] P. Fariselli,et al. Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach? , 2021, Gut.
[14] R. Ley,et al. The role of the microbiota in human genetic adaptation , 2020, Science.
[15] O. Pedersen,et al. Gut microbiota in human metabolic health and disease , 2020, Nature Reviews Microbiology.
[16] L. Kazak,et al. Creatine metabolism: energy homeostasis, immunity and cancer biology , 2020, Nature Reviews Endocrinology.
[17] Luis Pedro Coelho,et al. Statin therapy is associated with lower prevalence of gut microbiota dysbiosis , 2020, Nature.
[18] K. Clément,et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders , 2020, Nature Reviews Gastroenterology & Hepatology.
[19] K. Clément,et al. Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity? , 2020, Gastroenterology.
[20] R. Rodrigues,et al. Role of gut microbiota in type 2 diabetes pathophysiology , 2020, EBioMedicine.
[21] D. Halegoua-DeMarzio,et al. Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter? , 2019, Nutrients.
[22] E. Albano,et al. Adaptive immunity: an emerging player in the progression of NAFLD , 2019, Nature Reviews Gastroenterology & Hepatology.
[23] J. Venter,et al. Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease. , 2019, Cell metabolism.
[24] L. Hooper,et al. Immune control of the microbiota prevents obesity , 2019, Science.
[25] G. Reid,et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic , 2019, Nature Reviews Gastroenterology & Hepatology.
[26] J. Raes,et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study , 2019, Nature Medicine.
[27] Jonathan P. Jacobs,et al. Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver? , 2019, Experimental biology and medicine.
[28] K. Venema,et al. Gut microbial metabolites in obesity, NAFLD and T2DM , 2019, Nature Reviews Endocrinology.
[29] A. Ananthakrishnan,et al. Manipulating the Microbiome With Fecal Transplantation to Treat Ulcerative Colitis. , 2019, JAMA.
[30] William H. Bisson,et al. Gut microbiota and intestinal FXR mediate the clinical benefits of metformin , 2018, Nature Medicine.
[31] M. Netea,et al. The Inhibitory Innate Immune Sensor NLRP12 Maintains a Threshold against Obesity by Regulating Gut Microbiota Homeostasis. , 2018, Cell host & microbe.
[32] B. Schnabl,et al. Small metabolites, possible big changes: a microbiota-centered view of non-alcoholic fatty liver disease , 2018, Gut.
[33] P. Schneider,et al. B2‐Lymphocyte responses to oxidative stress‐derived antigens contribute to the evolution of nonalcoholic fatty liver disease (NAFLD) , 2018, Free radical biology & medicine.
[34] B. Neuschwander‐Tetri,et al. Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.
[35] P. Gentileschi,et al. Molecular Phenomics and Metagenomics of Hepatic Steatosis in Non-Diabetic Obese Women , 2018, Nature Medicine.
[36] Rob Knight,et al. Current understanding of the human microbiome , 2018, Nature Medicine.
[37] M. Nieuwdorp,et al. Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans , 2018, Endocrine reviews.
[38] A. Kurilshikov,et al. Environment dominates over host genetics in shaping human gut microbiota , 2018, Nature.
[39] Michael Charlton,et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.
[40] Ruixin Zhu,et al. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD , 2017, Gut.
[41] H. Chuang,et al. Nonalcoholic Fatty Liver Disease Is Exacerbated in High-Fat Diet-Fed Gnotobiotic Mice by Colonization with the Gut Microbiota from Patients with Nonalcoholic Steatohepatitis , 2017, Nutrients.
[42] A. Kariminik,et al. Gut Microbiota and IL-17A: Physiological and Pathological Responses , 2017, Probiotics and Antimicrobial Proteins.
[43] Louis J. Cohen,et al. Commensal bacteria produce GPCR ligands that mimic human signaling molecules , 2017, Nature.
[44] Alberto Martin,et al. Microbiome and colorectal cancer: Unraveling host-microbiota interactions in colitis-associated colorectal cancer development. , 2017, Seminars in immunology.
[45] Huijue Jia,et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention , 2017, Nature Medicine.
[46] K. Brandl,et al. Intestinal microbiota and nonalcoholic steatohepatitis , 2017, Current opinion in gastroenterology.
[47] Eveliina Munukka,et al. Faecalibacterium prausnitzii treatment improves hepatic health and reduces adipose tissue inflammation in high-fat fed mice , 2017, The ISME Journal.
[48] P. Paci,et al. Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta‐omics‐based approach , 2017, Hepatology.
[49] Tim Geach. Gut microbiota: Mucin-munching bacteria modulate glucose metabolism , 2017, Nature Reviews Endocrinology.
[50] S. Duncan,et al. Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics , 2017, The ISME Journal.
[51] R. Sartor,et al. Roles for Intestinal Bacteria, Viruses, and Fungi in Pathogenesis of Inflammatory Bowel Diseases and Therapeutic Approaches. , 2017, Gastroenterology.
[52] A. Waisman,et al. Metabolic Inflammation-Associated IL-17A Causes Non-alcoholic Steatohepatitis and Hepatocellular Carcinoma. , 2016, Cancer cell.
[53] Rohit Kohli,et al. IL-17 Signaling Accelerates the Progression of Nonalcoholic Fatty Liver Disease in Mice , 2014, Hepatology.
[54] Jie-shou Li,et al. Microbial fingerprinting detects intestinal microbiota dysbiosis in Zebrafish models with chemically-induced enterocolitis , 2013, BMC Microbiology.
[55] Xiaokang Wu,et al. Molecular Characterization of Fecal Microbiota in Patients with Viral Diarrhea , 2011, Current Microbiology.
[56] A. Palva,et al. Development of an extensive set of 16S rDNA‐targeted primers for quantification of pathogenic and indigenous bacteria in faecal samples by real‐time PCR , 2004, Journal of applied microbiology.
[57] J. Fujimoto,et al. Use of 16S rRNA Gene-Targeted Group-Specific Primers for Real-Time PCR Analysis of Predominant Bacteria in Human Feces , 2004, Applied and Environmental Microbiology.
[58] S. Finegold,et al. Real-Time PCR Quantitation of Clostridia in Feces of Autistic Children , 2004, Applied and Environmental Microbiology.
[59] M. Mcmurdo,et al. Characterization of Bacterial Communities in Feces from Healthy Elderly Volunteers and Hospitalized Elderly Patients by Using Real-Time PCR and Effects of Antibiotic Treatment on the Fecal Microbiota , 2004, Applied and Environmental Microbiology.
[60] C. Nishida,et al. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.